Basel, December 8, 2016 - Novartis today announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients with ...

Novartis NVS announced that the European Commission (EC) has approved Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]).It was granted ...

Smart inhaler tech company Propeller Health is collaborating with Novartis to bring its add-on sensor to its dry powder Breezhaler inhalers. Propeller's simple clip on sensor attaches to most asthma ...

European Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with ...

- Enerzair® Breezhaler® (QVM149) is a once-daily, potential first-in-class inhaled LABA/LAMA/ICS combination for asthma patients in the EU TOKYO and LONDON, May 1, 2020 /PRNewswire/ -- Sosei Group ...

Novartis studies show Onbrez® Breezhaler® plus tiotropium provided greater increase in lung function than tiotropium alone Two Phase III studies demonstrated efficacy benefits of combining once-daily ...

Enerzair® Breezhaler® plus sensor is the first asthma medication to be co-packaged and co-prescribed with a digital health platform MADISON, Wis.--(BUSINESS WIRE)--Propeller Health today announced a ...

Patients in Japan using Enerzair® and Atectura® Breezhaler® to treat uncontrolled asthma will now have access to Propeller’s digital health platform through their clinician MADISON, Wis.--(BUSINESS ...

Phase III studies show once-daily Onbrez Breezhaler plus tiotropium improved lung function (measured by trough FEV1) by up to 230 mL from baseline[1] Reported incidence of side effects was similar in ...

New analysis shows high-dose, once-daily Enerzair Breezhaler cut asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose A high dose of Novartis’ Enerzair Breezhaler ...

Vectura and Sosei Heptares exclusively licensed glycopyrronium bromide and certain intellectual property relating to its use and formulation to Novartis in April 2005. Novartis is responsible for the ...